Evidence map›Paper›PMID 41493435›Full record

ArticleInternational journal of laboratory hematology2026

ACMG/AMP-Based Variant Classification of a Novel HBA2 Variant (HBA2: C.297del, Hb Taiping) in Compound Heterozygosity With Hb Adana (HBA2:C.179G>A) Causing Non-Deletional Hb H Disease.

Norafiza Mohd Yasin, Suguna Somasundram, Syahzuwan Hassan, Nur Aisyah Aziz, Faidatul Syazlin Abdul Hamid, Ezzanie Suffya Zulkefli, Nor Nazuha Mohamad, Chin Ming Lee, Mohd Nazif Darawi, Thessalia Papasavva and 5 more

Abstract readCase Reports
In one paragraph

Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Norafiza Mohd YasinHaematology Unit, Cancer Research Centre (CaRC), Institute for Medical Research (IMR), National Institute for Health (NIH) Setia Alam, Setia Alam, Selangor, Malaysia.
Suguna SomasundramHaematology Unit, Cancer Research Centre (CaRC), Institute for Medical Research (IMR), National Institute for Health (NIH) Setia Alam, Setia Alam, Selangor, Malaysia.
Syahzuwan HassanHaematology Unit, Cancer Research Centre (CaRC), Institute for Medical Research (IMR), National Institute for Health (NIH) Setia Alam, Setia Alam, Selangor, Malaysia.
Nur Aisyah AzizHaematology Unit, Cancer Research Centre (CaRC), Institute for Medical Research (IMR), National Institute for Health (NIH) Setia Alam, Setia Alam, Selangor, Malaysia.ORCID https://orcid.org/0000-0002-4527-0704
Faidatul Syazlin Abdul HamidHaematology Unit, Cancer Research Centre (CaRC), Institute for Medical Research (IMR), National Institute for Health (NIH) Setia Alam, Setia Alam, Selangor, Malaysia.
Ezzanie Suffya ZulkefliHaematology Unit, Cancer Research Centre (CaRC), Institute for Medical Research (IMR), National Institute for Health (NIH) Setia Alam, Setia Alam, Selangor, Malaysia.
Nor Nazuha MohamadHaematology Unit, Pathology Department, Hospital Taiping, Taiping, Perak, Malaysia.
Chin Ming LeePaediatric Unit, Department of Medicine, Hospital Taiping, Taiping, Perak, Malaysia.
Mohd Nazif DarawiDepartment of Medical Diagnostics, Faculty of Health Sciences, University Selangor, Shah Alam, Selangor, Malaysia.
Thessalia PapasavvaMolecular Genetics Thalassaemia Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Coralea StephanouMolecular Genetics Thalassaemia Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Petros KountourisMolecular Genetics Thalassaemia Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
Sandra J G ArkesteijnDepartment of Clinical Genetics/GD, Leiden University Medical Centre, Leiden, the Netherlands.
Tamara KoopmanDepartment of Clinical Genetics/GD, Leiden University Medical Centre, Leiden, the Netherlands.
Cornelis L HarteveldDepartment of Clinical Genetics/GD, Leiden University Medical Centre, Leiden, the Netherlands.ORCID https://orcid.org/0000-0002-5135-6491

Funding

European Cooperation in Science and Technology
6 · The paper itself

Abstract

backgroundAccurate classification of novel globin gene variants is critical for the diagnosis and management of thalassaemia. The adaptation of ACMG/AMP guidelines for globin genes represents an important step toward standardising variant interpretation and enhancing clinical utility in the field. This study reports the haematological and molecular characteristics of a novel α2-globin variant identified in a Malay family.

methodsA Malay family from Taiping, Perak, Malaysia, with a history of α-thalassaemia, was recruited for this study. The proband's phenotype was assessed through comprehensive haematological analysis and clinical evaluation. Known α-thalassaemia deletions and non-deletional mutations were screened using gap-PCR and ARMS-PCR. Sanger sequencing of the HBA genes was conducted to characterise the proband's genotype in detail.

resultsA novel pathogenic HBA2 variant was identified, expanding the known mutational spectrum of α-thalassaemia. This variant introduces a premature stop codon, occurs in trans with a known pathogenic allele associated with a significant clinical phenotype, segregates with the disease in the family, and is absent from major population databases. Based on haematological data, molecular findings, in silico predictions, and protein modeling, the variant meets the ACMG/AMP criteria for pathogenicity adapted for α-globin genes. We have designated this variant Hb Taiping, named after the location of its discovery. Its accurate classification is vital for carrier screening, genetic counselling, and prenatal diagnosis, thereby supporting improved clinical management.

conclusionThis study identifies and characterises a novel α-globin gene variant, Hb Taiping, in a Malay family with α-thalassaemia. The discovery contributes to the growing body of pathogenic mutations linked to α-thalassaemia and underscores the importance of precise variant classification for effective diagnosis, risk assessment, and genetic counselling.

Indexed as

alpha-Globinsalpha-ThalassemiaHemoglobin A2Hemoglobins, AbnormalHeterozygoteMutationAdultFemaleHumansMalePedigreePhenotypealpha-GlobinsHemoglobin A2hemoglobin AdanaHemoglobins, Abnormalalpha‐thalassaemianovel variantvariant classification

Identifiers

PMID41493435
PMCPMC12956499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.